The signing ceremony of the Hunan Weitai cosmetic medicine comprehensive production base project was held recently. It has a total investment of 200 million yuan.

Guangdong WEITAI BIOTECHNOLOGY Co., Ltd. was established in 2012 and works closely with more than 1,000 raw material suppliers worldwide.

With tens of thousands of product formulas and lots of advanced production equipment such as lyophilizer and high shear vacuum emulsifier, it can produce a variety of dosage form products such as lyophilized powder, gel, stock solution, facial mask, cream.

As a subsidiary of Guangdong WEITAI BIOTECHNOLOGY Co., Ltd., Hunan Weitai Biopharmaceutical Co., Ltd. was established in 2021, mainly producing medical grade cosmetic products. It has 2 products that have obtained medical device registration certificates, and it is expected to obtain more than 10 medical device registration certificates in 2022.

This time, Hunan Weitai Biopharmaceutical plans to invest 200 million yuan to purchase the A4 factory building in the Cosmetic Valley, mainly developing and producing cosmetic medical products and emergency artery trauma hemostasis materials.

The latter has independent intellectual property rights, and the technology has reached the international leading level. The project is scheduled to be put into production on December 1 this year.

Subsequently, a project construction promotion meeting was held in the park, and the heads of relevant departments responded to the problems existing in the process of project construction.

In recent years, Ningxiang Economic and Technological Development Zone has focused on the cosmetic industry, and built the "Cosmetic Valley" industry platform, injecting a strong impetus into the park's development.